Zusammenfassung
Die zystische Fibrose (CF), auch Mukoviszidose genannt, ist eine der häufigsten autosomal rezessiven Erbkrankheiten mit einer Carrierfrequenz von 1:25; jedes 2500. Neugeborene ist davon betroffen. Während vor 50 Jahren ein Großteil der Kinder im ersten Lebensjahr starb, liegt die durchschnittliche Lebenserwartung heute bei ca. 30 Jahren.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Balistreri WF (1997) Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 24:573–589
Bargon J, Sanders S, Caspary WF, Buhl R (1995) Therapie der zystischen Fibrose im Erwachsenenalter— Gegenwart und Zukunft. Pneumologie 49:573–583
Bargon J, Stein J, Dietrich CF, Müller U, Caspary WF, Wagner TOF (1999) Gastrointestinale Komplikationen erwachsener Patienten mit zystischer Fibrose. Z Gastroenterol 37:739–749
Colombo C, Battezzati PM (1996) Hepatobiliary manifestations of cystic fibrosis. Eur J Gastroenterol Hepatol 8:748–754
Colombo C, Setchell KDR, Podda M, et. al., (1990) Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 117:482–489
Colombo C, Farrell P, Pencharz PB (1993) Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 82:562–565
Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A and the Italian Group for the Study of Ursodeoxyeholic Acid in Cystic Fibrosis (1996) Ursodeoxyeholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 23:1484–1490
Cotting J, Lentze MJ, Reichen J (1990) Effects of ursodeoxyeholic acid treatment on nutrition and life function in patients with cystic fibrosis and longstanding cholestasis. Gut 31:918–921
Lepage G, Paradis K, Lacaille F, et al., (1997) Ursodeoxyeholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr 130:52–58
Noble-Jamieson G, Valente J, Barnes ND, et al., (1994) Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child 71:349–352
Smith LJ, Lacaille F, Lepage G, Ronco N, Lamarre A, Roy CC (1991) Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. A randomized double-blind trial. Am J Dis Child 145:1401–1404
Sokol RJ, Durie PR for the Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group (1999) Recommendations for the management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 28:S1-S13
Westaby D (1995) Liver and biliary disease im cystic fibrosis. In: Hodson ME, Geddes DM (Hrsg) Cystic fibrosis. Chapman and Hall Medical, London, S 281-293
Yang Y, Raper SE, Cohn JA, Engelhardt JF, Wilson JM (1993) An approach for treating hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci USA 90:4601–4605
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bargon, J., Caspary, W.F. (2001). Zystische Fibrose. In: Caspary, W.F., Leuschner, U., Zeuzem, S. (eds) Therapie von Leber- und Gallekrankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56819-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-56819-0_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63151-1
Online ISBN: 978-3-642-56819-0
eBook Packages: Springer Book Archive